The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(R)-3-methyl-4-(6-(1-methyl-1H-pyrazol-5-yl)-2-(1H-pyrazol-4-yl)quinazolin-4-yl)morpholine ID: ALA5204030
PubChem CID: 168293787
Max Phase: Preclinical
Molecular Formula: C20H21N7O
Molecular Weight: 375.44
Associated Items:
Names and Identifiers Canonical SMILES: C[C@@H]1COCCN1c1nc(-c2cn[nH]c2)nc2ccc(-c3ccnn3C)cc12
Standard InChI: InChI=1S/C20H21N7O/c1-13-12-28-8-7-27(13)20-16-9-14(18-5-6-23-26(18)2)3-4-17(16)24-19(25-20)15-10-21-22-11-15/h3-6,9-11,13H,7-8,12H2,1-2H3,(H,21,22)/t13-/m1/s1
Standard InChI Key: MFEWEGOWHRFZDB-CYBMUJFWSA-N
Molfile:
RDKit 2D
28 32 0 0 0 0 0 0 0 0999 V2000
-0.7162 -0.9059 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.0024 -1.3195 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.0024 -2.1488 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.7131 -2.5676 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
1.4289 -2.1489 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.4289 -1.3196 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.7133 -0.9091 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.7133 -0.0842 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.4308 0.3291 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.4308 1.1588 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.7112 1.5748 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.0016 1.1568 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.0016 0.3272 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.7186 -0.0832 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.4346 0.3272 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.4346 1.1568 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.7186 1.5758 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.1484 -0.0862 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.9015 0.2505 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.4538 -0.3639 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.0415 -1.0800 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-2.2309 -0.9073 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-1.6165 -1.4578 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.1451 1.5715 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.9004 1.2366 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.4538 1.8503 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
3.0385 2.5676 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2.2321 2.3918 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2 1 1 1
3 2 1 0
4 3 1 0
4 5 1 0
6 5 1 0
2 7 1 0
7 6 1 0
8 7 1 0
9 8 2 0
10 9 1 0
11 10 2 0
12 11 1 0
13 12 2 0
13 8 1 0
13 14 1 0
14 15 2 0
15 16 1 0
16 17 2 0
12 17 1 0
18 15 1 0
19 18 2 0
20 19 1 0
21 20 2 0
22 21 1 0
22 18 1 0
23 22 1 0
24 10 1 0
25 24 1 0
26 25 2 0
27 26 1 0
24 28 2 0
27 28 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Topical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 375.44Molecular Weight (Monoisotopic): 375.1808AlogP: 2.65#Rotatable Bonds: 3Polar Surface Area: 84.75Molecular Species: NEUTRALHBA: 7HBD: 1#RO5 Violations: ┄HBA (Lipinski): 8HBD (Lipinski): 1#RO5 Violations (Lipinski): ┄CX Acidic pKa: 10.19CX Basic pKa: 4.03CX LogP: 2.92CX LogD: 2.91Aromatic Rings: 4Heavy Atoms: 28QED Weighted: 0.59Np Likeness Score: -1.69
References 1. Bin H, Chen P, Wu M, Wang F, Lin G, Pan S, Liu J, Mu B, Nan J, Huang Q, Li L, Yang S.. (2022) Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase: Structural activity relationship and antitumor activity both in vitro and in vivo., 232 [PMID:35183872 ] [10.1016/j.ejmech.2022.114187 ]